A new biomarker has been identified, which indicates the progression of the disease in the patient and their response to specific drug therapies, reveals a new study.
Scientists at the Icahn School of Medicine at Mount Sinai, Sema4, and collaborating institutions including Colorado State University and Fred Hutchinson Cancer Center reported results from a glioblastoma study in the issue of Cancer Research.
Glioblastoma Multiforme
Glioblastomas are tumors that arise from astrocytes that make up the supportive tissue of the brain. Glioblastomas are usually highly malignant.
Advertisement
‘Further research is required to develop a diagnostic test that can help physicians understand and treat patients better.’
Tweet it Now
Glioblastoma is a highly aggressive and heterogeneous form of brain cancer, with a median survival time from diagnosis of just one year. Previous efforts to classify glioblastoma tumors into molecular subtypes for precision treatment have been largely unsuccessful.
In this study, scientists developed an innovative computational method to classify tumors based on their dependency on a molecule, known as BUB1B, that some glioblastomas need to survive.
![Patient Survival In Glioblastoma Depends on DNA Modifications]( "Patient Survival In Glioblastoma Depends on DNA Modifications")
Study shows the distribution of a DNA defect in the glioblastoma genome and its relationship with patient survival.
The project revealed new tumor subtypes and found that BUB1B-sensitive tumors had significantly worse prognosis but were more likely to respond to many drugs already in clinical use.
"It was truly remarkable to see our predictive model yield a new set of molecular subtypes, which appear to be far more indicative of prognosis and therapeutic response than existing subtypes," said Jun Zhu, PhD, Head of Data Sciences at Sema4, Professor of Genetics and Genomic Sciences at Mount Sinai, and senior author of the paper.
"For patients who receive the grim diagnosis of glioblastoma, this signals new hope for tailored treatment more likely to be effective against their cancer."
"This research is an outstanding example of how theoreticians working with complex datasets, and clinicians on the frontlines of patient care, can collaborate to uncover new insights into cancer biology that will directly impact clinical decision-making," said Raymund Yong, MD, Assistant Professor of Neurosurgery and Assistant Professor of Oncological Sciences at the Icahn School of Medicine at Mount Sinai, who made a significant contribution to tumor samples, glioma stem cells, and in vitro experiments in the paper.
Eric Schadt, PhD, Sema4 CEO and Dean for Precision Medicine at Mount Sinai, added:
"These findings underscore the significant potential we see to improve patient outcomes by investing in predictive modeling of even the most complex types of cancer. We look forward to building on this collaborative project and moving toward development of a diagnostic test that could help physicians better understand and treat their patients' glioblastoma cases."
Source: Eurekalert
Patient Survival In Glioblastoma Depends on DNA Modifications
Study shows the distribution of a DNA defect in the glioblastoma genome and its relationship with patient survival.
Advertisement
The project revealed new tumor subtypes and found that BUB1B-sensitive tumors had significantly worse prognosis but were more likely to respond to many drugs already in clinical use.
"It was truly remarkable to see our predictive model yield a new set of molecular subtypes, which appear to be far more indicative of prognosis and therapeutic response than existing subtypes," said Jun Zhu, PhD, Head of Data Sciences at Sema4, Professor of Genetics and Genomic Sciences at Mount Sinai, and senior author of the paper.
"For patients who receive the grim diagnosis of glioblastoma, this signals new hope for tailored treatment more likely to be effective against their cancer."
"This research is an outstanding example of how theoreticians working with complex datasets, and clinicians on the frontlines of patient care, can collaborate to uncover new insights into cancer biology that will directly impact clinical decision-making," said Raymund Yong, MD, Assistant Professor of Neurosurgery and Assistant Professor of Oncological Sciences at the Icahn School of Medicine at Mount Sinai, who made a significant contribution to tumor samples, glioma stem cells, and in vitro experiments in the paper.
Eric Schadt, PhD, Sema4 CEO and Dean for Precision Medicine at Mount Sinai, added:
"These findings underscore the significant potential we see to improve patient outcomes by investing in predictive modeling of even the most complex types of cancer. We look forward to building on this collaborative project and moving toward development of a diagnostic test that could help physicians better understand and treat their patients' glioblastoma cases."
Source: Eurekalert
Possible Molecular Basis to Associations Between Alzheimer’s Disease, Glioblastoma and Lung Cancer Identified
Genetic changes may be able to explain increased risk of glioblastoma in Alzheimer's disease and inverse association of the disease to lung cancer.
Advertisement
Advertisement
|
Advertisement
Recommended Reading
Latest Cancer News
New study evaluated the association between exposure to the chemical agent orange and the development of blood cancer with increased bleeding and blood clot formation.
Study suggests two-year immunotherapy treatment for advanced lung cancer may be reasonable
A ray of hope for glioma patients as targeted therapy boosts treatment duration.
In patients with breast cancer combination therapy had increased invasive disease-free survival compared to those who were treated with the hormone therapy alone.
An antibody treatment helped shrink tumors in some patients with bile duct cancers.